Kane Biotech Inc.
KNE.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.60M | -1.93M | -2.32M | -2.37M | 4.61M |
| Total Depreciation and Amortization | 96.70K | 116.30K | 138.50K | 146.20K | 152.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.10K | 47.40K | 351.40K | 481.50K | -6.98M |
| Change in Net Operating Assets | -355.30K | -552.40K | -309.10K | -281.20K | -832.70K |
| Cash from Operations | -1.90M | -2.32M | -2.13M | -2.02M | -3.05M |
| Capital Expenditure | 0.00 | -9.60K | -12.80K | -16.50K | -24.00K |
| Sale of Property, Plant, and Equipment | 50.00K | 50.00K | 50.00K | 6.40K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 402.50K | 42.80K | 7.04M |
| Other Investing Activities | -65.00K | -77.40K | -438.40K | -77.10K | -416.90K |
| Cash from Investing | -15.00K | -36.90K | 1.40K | -44.30K | 6.59M |
| Total Debt Issued | 972.50K | 972.50K | 1.00M | 1.00M | -- |
| Total Debt Repaid | -158.00K | -306.80K | -443.60K | -576.10K | -6.62M |
| Issuance of Common Stock | 1.78M | 3.23M | 2.91M | 3.16M | 2.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -30.20K | -40.90K | -75.00K | -80.10K | -1.46M |
| Cash from Financing | 1.85M | 2.75M | 2.41M | 2.50M | -4.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -71.30K | 386.90K | 281.10K | 429.10K | -887.10K |